Verona Pharma's Participation in Major Healthcare Conferences
Verona Pharma plc (Nasdaq: VRNA) is gearing up for a busy June as it announces participation in several important investor conferences. These events provide a platform for the company to share insights on its innovative therapies for respiratory diseases and engage with investors directly.
Key Conferences in June
The conferences where senior management from Verona Pharma will be featured include:
Jefferies Global Healthcare Conference
This event is scheduled for Wednesday, June 4, 2025, at 11:05 a.m. ET / 4:05 p.m. BST. It will take place in New York City, providing a significant opportunity for dialogue about the company's latest advancements in medical treatments.
Goldman Sachs 46th Annual Global Healthcare Conference
The Goldman Sachs event will follow closely on Monday, June 9, 2025, at 2:40 p.m. ET / 7:40 p.m. BST in Miami, Florida. This conference is another pivotal gathering where Verona Pharma can highlight its commitment to addressing chronic respiratory conditions.
Accessing Webcast Presentations
Both conferences will feature webcasts of the presentations, which will be accessible via the Events and Presentations section on the Company's Investors page. Interested parties can easily tune in to learn more about Verona Pharma’s strategic direction and product development initiatives.
Who to Contact for More Information
For investors and media inquiries, Verona Pharma offers several contact points to facilitate discussions:
Investor Relations
For further information regarding investment opportunities, you can reach out to:
Verona Pharma plc
Tel: +1-844-341-9901
Email: IR@veronapharma.com
USA Investor Inquiries
If you are in the U.S. and have inquiries, please contact:
Argot Partners
Tel: +1-212-600-1902
Email: verona@argotpartners.com
About Verona Pharma
Verona Pharma is dedicated to the development and commercialization of cutting-edge therapies aimed at chronic respiratory diseases that remain challenging to treat. Their flagship product, Ohtuvayre (ensifentrine), stands out as the first inhaled therapy combining bronchodilator and anti-inflammatory properties for maintaining treatment in COPD. This dual mechanism not only offers an innovative approach but also holds promise for conditions like non-cystic fibrosis bronchiectasis, cystic fibrosis, and asthma.
Frequently Asked Questions
What is the purpose of the conferences Verona Pharma is attending?
The conferences are intended for Verona Pharma to present its innovative therapies and engage with investors to discuss future strategies and developments.
When will the presentations be available for viewing?
The webcast presentations will be made available on the company's Investors page following each conference event.
Who should I contact for investor relations inquiries?
For investor relations inquiries, you can contact Verona Pharma directly via phone at +1-844-341-9901 or by emailing IR@veronapharma.com.
What is Ohtuvayre and its significance?
Ohtuvayre is Verona Pharma’s first commercial product that uniquely combines bronchodilator and anti-inflammatory actions, representing a significant breakthrough for COPD treatment.
How can I get more information about Verona Pharma?
More information about Verona Pharma and its products can be found on their official website, which provides updates and resources on their therapeutic approaches.
